WO2008102128A2 - Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid - Google Patents

Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid Download PDF

Info

Publication number
WO2008102128A2
WO2008102128A2 PCT/GB2008/000578 GB2008000578W WO2008102128A2 WO 2008102128 A2 WO2008102128 A2 WO 2008102128A2 GB 2008000578 W GB2008000578 W GB 2008000578W WO 2008102128 A2 WO2008102128 A2 WO 2008102128A2
Authority
WO
WIPO (PCT)
Prior art keywords
combination
pharmaceutically acceptable
ester
acceptable salt
propellant
Prior art date
Application number
PCT/GB2008/000578
Other languages
French (fr)
Other versions
WO2008102128A3 (en
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Limited
Curtis, Philip, Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39523694&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008102128(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Limited, Curtis, Philip, Anthony filed Critical Cipla Limited
Priority to EP08709463A priority Critical patent/EP2124915A2/en
Priority to CA002677573A priority patent/CA2677573A1/en
Priority to MX2009008794A priority patent/MX2009008794A/en
Priority to US12/527,096 priority patent/US20100063016A1/en
Priority to JP2009549477A priority patent/JP2010519195A/en
Priority to AU2008217586A priority patent/AU2008217586A1/en
Publication of WO2008102128A2 publication Critical patent/WO2008102128A2/en
Publication of WO2008102128A3 publication Critical patent/WO2008102128A3/en
Priority to US13/683,162 priority patent/US20130074834A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to combinations of inhalable medicaments for simultaneous or sequential administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
  • COPD chronic obstructive pulmonary disease
  • the airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking.
  • Bronchodilators and steroids form the major classes of drugs used.
  • WOO 139745 discloses dry powder inhalation comprising formoterol and its salts or derivatives thereof and pharmaceutically acceptable particulate diluent.
  • WO0207672 relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising water.
  • the medicament is selected from the group consisting of albuterol, atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisone, mometasone, triamcinolone acetonide, salmeterol, amiloride, fluticasone, (-) 4-amino-3,5- dichloro-a- [ [ [6 (2pyridinyl) ethoxy] hexyl] amino] methyl] benzene-methanol and pharmaceutically acceptable salts, esters, hydrates and solvates of the
  • US6423298 relates to pharmaceutical formulations for aerosols with at least two or more active substances for administration by inhalation or by nasal route.
  • WO2004019985 discloses certain other drug pharmaceutical formulations for aerosols.
  • the treatment calls for the patient to comply with different dosage regimens, different frequencies of administration, etc. Also, since most of the medications are in the form of aerosols, the patient is required to carry several formulations and dispensers.
  • It is an object of the present invention is to provide combinations of inhalable medicaments for administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
  • a pharmaceutical combination comprising at least two active substances for once daily administration by inhalation route.
  • a pharmaceutical combination comprising at least two active substances for once daily administration by inhalation route administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
  • the present invention provides novel combinations comprising two or more actives for administration once daily.
  • the actives may be selected from various classes consisting of bronchodilators and corticosteroids and mixtures thereof.
  • the bronchodilators may be either beta-agonists or anticholinergics or both.
  • corticosteroids shows a synergistic effect by relaxing both the central and peripheral air pathways improving the airflow obstruction, prolonged bronchodilation and provides rapid onset of action with reduced exacerbations.
  • Pharmaceutically active agents useful in the present invention include one or more of drugs selected from various classes consisting of bronchodilators and corticosteroids and mixtures thereof.
  • the bronchodilators may be beta-agonists and/or anticholinergics.
  • beta- agonist agent or “beta-agonist” or “anticholinergic agent” or “corticosteroids” are used in broad sense to include not only the beta-agonist or anticholinergic agent per se but also their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, etc.
  • the beta-agonists may be selected from formoterol, AR-formoterol, fenoterol, carmoterol, indacaterol and the like.
  • Formoterol may be present in an amount ranging from about 4.5- 96 meg
  • AR-formoterol may be present in an amount ranging from 1.25-96 meg
  • carmoterol may be present in an amount ranging from 0.5-16 meg
  • indacaterol may be present in an amount ranging from 25-800 meg.
  • the anticholinergic may be aclidinium, ipratropium, tiotropium, oxitropium and the like.
  • Tiotropium may be present in an amount ranging from 4.5 - 160 meg.
  • Aclidinium may be present in an amount ranging from 50 - 900 meg.
  • the corticosteroid may be budesonide, ciclesonide, mometasone, beclomethasone and the like. Ciclesonide may be present in an amount ranging from 40-2880 meg and mometasone present in an amount ranging from 25-2000 meg.
  • the beta agonist is carmoterol
  • the corticosteroid is ciclesonide
  • the anticholinergic is tiotropium
  • the beta agonist is carmoterol
  • the corticosteroid is ciclesonide.
  • the anticholinergic is tiotropium and the beta agonist is carmoterol.
  • the anticholinergic is aclidinium and the beta agonist is formoterol and/or AR-formoterol.
  • MDIs metered dose inhalers
  • aerosols are compact drug delivery systems that use a liquefied propellant to atomize a precisely metered volume of a pharmaceutical formulation into particles, which are small enough to penetrate deep into the patient's lungs. MDIs allow for targeted delivery of drug to the desired site of the therapeutic effect - the lung.
  • the pharmaceutical combination may further be combined with one or more pharmaceutically acceptable excipients in order to provide a suitable formulation.
  • the combination may, for example, be formulated as a propellant free inhalation solution for nebulization, as an aerosol composition (with propellant), or as dry powder composition for inhalation.
  • the drugs may be used alone or optionally together with a finely divided pharmaceutically acceptable carrier, which is preferably present and may be chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides; and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol.
  • a finely divided pharmaceutically acceptable carrier which is preferably present and may be chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides; and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol.
  • the pharmaceutically acceptable carrier in the dry powder inhalation formulation is lactose.
  • the carrier is preferably present in an amount not less that 75% by weight of the formulation.
  • the dry powder may be provided in capsules of gelatin or HPMC or in blisters or alternatively, the dry powder may be contained as a reservoir either in a single dose or multi- dose dry powder inhalation device.
  • the particle size of the active ingredient and that of the carrier where present in dry powder compositions, can be reduced to the desired level by conventional methods, for example by grinding in an air-jet mill, ball mill or vibrator mill, microprecipitation, spray-drying, lyophilization or recrystallization from supercritical media.
  • the above dry powder composition may be manufactured by any convenient means wherein the process comprises of two or more drugs being mixed optionally with a pharmaceutically acceptable carrier and providing the ingredients in a suitable dry powder inhaler.
  • the drugs may be combined with suitable excipients such as wetting agents, tonicity adjusting agents, pH regulators, buffering agents and chelating agents, in a suitable vehicle.
  • the wetting agents may be selected from the group consisting of sodiumdioctylsulfosuccinate; polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 65, polysorbate 85; sorbitan fatty acid esters such as Span 20, Span 40, Span 60 Span 80, Span 120; sodium lauryl sulfate; polyethoxylated castor oil; polyethoxylated hydrogenated castor oil and the like.
  • the preferred wetting agent is one or more polysorbates, either alone or in combination with another wetting agent.
  • the amount of wetting agent (especially when it includes a polysorbate) is in a range of 0.001 to 0.1% w/v of the composition.
  • the tonicity-adjusting agent which may be used in the present invention, may include one or more of sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof.
  • the preferred tonicity adjusting agent is sodium chloride.
  • the pH regulator may be selected from pharmacologically acceptable inorganic acids or organic acids, such as sodium hydroxide, sodium carbonate, sodium bicarbonate, magnesium carbonates, aluminium hydroxide, aluminum carbonate, aluminium bicarbonate, calcium carbonate and calcium hydroxide, calcium bicarbonate and the like.
  • the preferred inorganic acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid and the like.
  • the preferred organic acids are selected from the group consisting of ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid.
  • the most preferred inorganic acids are hydrochloric acid & sulphuric acid, while, for the organic acids, ascorbic acid, citric acid and fumaric acid are the most preferred.
  • the pH regulators may be selected from pharmacologically acceptable inorganic bases or organic bases.
  • the preferred inorganic bases are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide.
  • the preferred organic bases are selected from the group consisting of methyl amine, ethyleneimine, hydroquinone, ethylamine, dimethylamine, ethanolamine, butylamine, diethylamine. The most preferred base is sodium hydroxide.
  • a nasal inhalation formulation as provided by the present invention has a pH in the range of 3.0 to 7.0.
  • suitable chelating or complexing agents are used in the inhalation solutions, and may be molecules which are capable of entering into complex bonds.
  • the formulations according to the invention preferably contain EDTA or one of the known salts thereof, e.g. sodium EDTA or disodium EDTA dihydrate, as complexing agent.
  • the preferred agent is ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt.
  • suitable buffering agents that may be used in the inhalation solutions include citric acid and sodium or potassium citrates; or phosphates like trisodium phosphate, disodium or trisodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, tripotassium hydrogen phosphate and the like.
  • Suitable liquid vehicles for use in the compositions of the invention include polar solvents, such as compounds that contain hydroxyl groups or other polar groups.
  • polar solvents such as compounds that contain hydroxyl groups or other polar groups.
  • solvents may include water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
  • Suitable polar solvents also include protic solvents, such as water, one or more aqueous saline solutions with one or more pharmaceutically acceptable salt(s), one or more alcohols, one or more glycols or a mixture thereof.
  • protic solvents such as water, one or more aqueous saline solutions with one or more pharmaceutically acceptable salt(s), one or more alcohols, one or more glycols or a mixture thereof.
  • suitable salts are those which display no or only negligible pharmacological activity after administration.
  • An anti-microbial preservative agent may be added for multi-dose packages. Suitable preservatives will be apparent to the skilled person, particularly benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate, sorbic acid or sorbates such as potassium sorbates in the concentration known from the prior art. The most preferred preservative is benzalkonium chloride.
  • the above inhalation or nebulizer composition may be manufactured by any convenient means wherein the process comprises dissolving two or more drugs and optionally chelating agents, tonicity adjusting agents and any other suitable ingredient in a vehicle and adjusting the pH using a suitable pH adjusting agent. Further, finally, providing the said composition in a suitable dispensing container (such as a nebulizer) for inhalation.
  • a suitable dispensing container such as a nebulizer
  • the above composition can be manufactured by convenient means wherein the process comprises sterilization of the active/s by known processes such as dry heat sterilization, moist heat sterilization, gamma radiation.
  • the sterilized active/s is/are placed in a container and sterile bulk of other pharmaceutically acceptable ingredients comprising one or more of wetting agents, tonicity adjusting agents, pH regulators, chelating agents, buffering agents are transferred aseptically in the container with the API.
  • the mixture may then be subjected to mixing either by sonication or magnetic stirring or by other means known in the art and finally, adding the above solution to the remaining bulk.
  • the formulations may comprise one or more of cosolvents, antioxidants, surfactants, bulking agents and lubricants, in addition to the actives and propellant.
  • the actives may be combined with one or more propellants.
  • the present invention includes at least one propellant such as propellant 11 (dichlorodifluoromethane), propellant 12 (monofluorotrichloromethane), Propellant 114, 1,1,1 ,2-tetrafiuoroethane, 1 , 1 , 1 ,2,3 ,3 ,3 -heptafluoroethane
  • propellant 11 dichlorodifluoromethane
  • propellant 12 monofluorotrichloromethane
  • Propellant 114 1,1,1 ,2-tetrafiuoroethane, 1 , 1 , 1 ,2,3 ,3 ,3 -heptafluoroethane
  • the actives may be combined with either propellant 11 or propellant 114 or a combination thereof of and propellant 12 with surface- active agents known in the art.
  • the surfactants may be selected from the vast class known in the art like oils such as corn oil, olive oil, cottonseed oil and sunflower seed oil, mineral oils like liquid paraffin, oleic acid and also phospholipids such as lecithin, or sorbitan fatty acid esters like sorbitan trioleate or Tween 20, Tween 60, Tween 80, PEG - 25 Glyceryl trioleate, PVP, citric acid, PFDA (per fluoro-n-decanoic acid)
  • the use of surfactants leads to comparatively good suspension quality.
  • One of the preferred surfactants is lecithin.
  • the surfactant can be used in a concentration of 0.001-100%. Preferably in a range of 1% - 50%. More preferably in a concentration of 5% - 30%. These concentrations are based on the weight of the active material(s).
  • the actives and the surfactant can be micro- milled with propellant, preferably propellant 11 or propellant 114 or a combination thereof, to form a slurry and then the slurry can be filled in canisters.
  • the actives can be micro-milled separately or together with the propellant. Micro-milling can be done to improve the suspension quality which inurn results in a better FPD.
  • a method for the manufacture of CFC aerosol which process comprises: (a) optionally micro- milling the drugs and surfactant with a propellant, preferably either propellant 11 or propellant 114 or a combination thereof; (b) filling the slurry in the canisters; (c) crimping with a suitable valve; and (d) charging with a propellant, preferably propellant 12, through the valve.
  • a propellant preferably either propellant 11 or propellant 114 or a combination thereof
  • the aerosol composition may comprise actives and either 1,1,1,2-tetrafluoroethane (HFA134a) or 1,1,1,2,3,3,3-heptafluoroethane (HFA227) or a combination thereof.
  • HFA134a 1,1,1,2-tetrafluoroethane
  • HFA22-7 1,1,1,2,3,3,3-heptafluoroethane
  • Another embodiment of the present invention may comprise actives, propellant and a cosolvent.
  • the cosolvent has a greater polarity than the propellant.
  • the cosolvent is present in a proportion of 0.2 to 20% by weight of the total formulation.
  • the cosolvent used may be selected from the group consisting of glycols, particularly propylene glycol, polyethylene glycol and glycerol or ethanol and mixtures thereof.
  • the cosolvent is ethanol.
  • the present invention also provides a method for the manufacture of the above composition which method comprises (a) Addition of the active ingredients to the canister, (b) Addition of the cosolvent optionally to (a) and sonication of the same, (c) Crimping the canister with the metered valve (d) charging the canister with the propellant.
  • the present invention may comprise the actives, propellant, surface-active agent and cosolvent.
  • the surface-active agent stabilizes the formulation and helps in the lubrication of a valve system in the inhaler.
  • Some of the most commonly used surface active agents are those known in the art and can be selected from among various polysorbates such as Polysorbate 20, Polysorbate 40, Polysorbate 80; Acetylated monoglycerides like Myvacet 9-45 and Myvacet 9-08; isopropylmyristate, oleic acid, Polyoxyethylene ethers, ethyloleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oils, polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, polyethoxylated sorbitan fatty acid esters (
  • the surface-active agents are preferably used in a concentration of 0.02 - 10% by weight of the active ingredients.
  • the present invention also provides a method for the manufacture of the above composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the cosolvent and the surfactant solution to (a) and sonication of the same; (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
  • Another embodiment of the present invention comprises the actives along with bulking agent and propellant.
  • the bulking agent acts as a carrier for the drug to reach the lungs.
  • the bulking agent may be present in a concentration of 10-500% by weight of the active. More preferably in a range of 10-300% by weight of the active.
  • the bulking agent may be selected from the class of saccharides, including monosaccharides, disaccharides, polysaccharides; and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol.
  • the preferred bulking agent is lactose.
  • the present invention also provides a method for the manufacture of the above aerosol composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the bulking agent to (a); (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
  • Yet another embodiment of the present invention comprises the actives along with surfactant and propellant.
  • the surfactant may be selected from the class of salts of stearic acids or esters such, as ascorbyl palmitate, isopropyl myristate and tocopherol esters.
  • the surfactant is preferably the magnesium salt of stearic acid or isopropyl myristate. Most preferably the surfactant is magnesium stearate.
  • the surfactant is preferably used in a concentration of 0.01% to 10% by weight of the active.
  • the present invention also provides a method for the manufacture of the above aerosol composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the surfactant to (a); (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
  • one or more actives can be spray-coated or spray-dried or co- precipitated.
  • the spray coating, spray drying or co-precipitation may be done by mixing the active in a solution of surface active agents in a suitable non-polar solvent and further removing the solvent.
  • a method for the treatment in a mammal such as a human, of chronic obstructive pulmonary disease, which method comprises administration of a therapeutically effective amount ranging from a pharmaceutical composition according to the present invention.
  • the MDI formulations may be in plain aluminium cans or SS (stainless steel) cans.
  • Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the cans and valves, of the
  • Suitable coatings include fluorocarbon copolymers such as FEP-PES (fluorinated ethylene propylene and polyethersulphone) and PFA-PES (perfluoroalkoxyalkane and polyethersulphone), epoxy and ethylene.
  • the inner surfaces of the cans may be anodized.
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with a propellant, which is preferably HFA P227.
  • a propellant which is preferably HFA P227.
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with lactose and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide (spray coated with PVP), with lactose and a propellant, which is preferably HFA P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with PEG 100 and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • Example 5 An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, oleic acid, and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, sorbitan trioleate, citric acid and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin, hydrochloric acid, and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with a propellant, which is preferably HFA P227.
  • a propellant which is preferably HFA P227.
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with lactose and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol fo ⁇ nulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide spray coated with PVP, with lactose and a propellant, which is preferably HFA P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with PEG 100 and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, oleic acid and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, sorbitan trioleate, citric acid and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • Example 16 An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin, hydrochloric acid and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12.
  • the amounts of the materials is preferably as shown in the table:
  • Example 18 An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with lecithin and a propellant, which is preferably Propellant 1 1 and Propellant 114 in combination with Propellant 12.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with oleic acid and a propellant, which is preferably Propellant 11 and Propellant 12.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with sorbitan trioleate and a propellant, which is preferably Propellant 11 and Propellant 12.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with oleic acid and a propellant, which is preferably Propellant 11 and Propellant 114 in combination with Propellant 12 .
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with sorbitan trioleate and a propellant, which is preferably Propellant 11 and Propellant 114 in combination with Propellant 12.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with ethanol and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with ethanol and a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with oleic acid, ethanol and a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with oleic acid, ethanol and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • Example 29 An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with lactose and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with lactose and a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with magnesium stearate and a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with magnesium stearate and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with isopropyl myristate and a propellant, which is preferably Propellant P227.
  • the amounts of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with isopropyl myristate and a propellant, which is preferably HFA 134a.
  • the amounts of the materials is preferably as shown in the table:
  • the present invention may be manufactured by convenient means wherein the process comprises of one or more drugs being mixed optionally with a pharmaceutically acceptable carrier and providing the ingredients in a suitable dry powder inhaler ready for inhalation.
  • An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with lactose.
  • the amount of the materials is preferably as shown in the table:
  • An dry powder formulation was prepared using carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide and lactose.
  • the amount of the materials is preferably as shown in the table:
  • An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide and lactose.
  • the amount of the materials is preferably as shown in the table:
  • Example 38 An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and formoterol, or a salt thereof, preferably formoterol fuinarate dehydrate in combination with budesonide and lactose.
  • the amount of the materials is preferably as shown in the table:
  • An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and formoterol, or a salt thereof, preferably formoterol fumarate dehydrate in combination with budesonide and lactose.
  • the amount of the materials is preferably as shown in the table:
  • the present invention may be carried out by a process comprising placing a sterile active(s) in a suitable container, then, aseptically adding the sterile bulk of other ingredients to the container having the active(s) and mixing the above solution by sonication or magnetic stirring and finally adding the above mixture to the remaining bulk.
  • a sterile active(s) placed in a suitable container, then, aseptically adding the sterile bulk of other ingredients to the container having the active(s) and mixing the above solution by sonication or magnetic stirring and finally adding the above mixture to the remaining bulk.
  • An inhalation solution formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide, Tween 20, sodium chloride and water.
  • the amount of the materials is preferably as shown in the table:
  • An inhalation solution formulation was prepared using carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide, Tween 20, sodium chloride and water.
  • the amount of the materials is preferably as shown in the table:
  • An inhalation solution formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with sodium chloride and water.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12.
  • the amount of the materials is preferably as shown in the table:
  • Example 44 An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and ciclesonide, in combination with lecithin and a propellant, which is preferably Propellant 1 1 and Propellant 12.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with a propellant, which is preferably HFAl 34a.
  • a propellant which is preferably HFAl 34a.
  • the amount of the materials is preferably as shown in the table:
  • Example 46 An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with lactose and a propellant, which is preferably HFA 227.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and ciclesonide, in combination with a propellant, which is preferably HFA 134a.
  • a propellant which is preferably HFA 134a.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmeterol, or a salt thereof, ciclesonide, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 20 12.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using ciclesonide and formoterol, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using carmoterol or a salt thereof and ciclesonide, in combination with a propellant, which is preferably HFA 134a.
  • a propellant which is preferably HFA 134a.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and ciclesonide, in combination with a propellant, which is preferably HFA 134a.
  • a propellant which is preferably HFA 134a.
  • the amount of the materials is preferably as shown in the table:
  • An aerosol formulation was prepared using formoterol and ciclesonide, in combination with ethanol, lecithin and a propellant, which is preferably HFA 227.
  • the amount of the materials is preferably as shown in the table:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.

Description

Pharmaceutical Combinations
Technical field:
The present invention relates to combinations of inhalable medicaments for simultaneous or sequential administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
Background & Prior art:
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking.
It is expected to be the third leading cause of death by 2020. Approximately 14 million Indians are currently suffering form COPD. Currently there are 94 million smokers in India.10 lakh Indians die in a year due to smoking related diseases
Although COPD affects the lungs, it also produces significant systemic consequences.
Various therapies are currently used for the treatment of COPD. Bronchodilators and steroids form the major classes of drugs used.
WOO 139745 discloses dry powder inhalation comprising formoterol and its salts or derivatives thereof and pharmaceutically acceptable particulate diluent.
A combination therapy is described in patent number WOO 176601, using short acting anticholinergic ipratropium bromide and long acting β-agonist salmeterol are. A further combination therapy, using steroid along with anticholinergics and beta agonist, has been described in US6423298 and WO0207672.
WO0207672 relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, or combination of at least two particulate drugs a propellant and a stabilizing agent comprising water. The medicament is selected from the group consisting of albuterol, atropine, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisone, mometasone, triamcinolone acetonide, salmeterol, amiloride, fluticasone, (-) 4-amino-3,5- dichloro-a- [ [ [6 (2pyridinyl) ethoxy] hexyl] amino] methyl] benzene-methanol and pharmaceutically acceptable salts, esters, hydrates and solvates of the foregoing.
US6423298 relates to pharmaceutical formulations for aerosols with at least two or more active substances for administration by inhalation or by nasal route.
WO2004019985 discloses certain other drug pharmaceutical formulations for aerosols.
Various other combinations are known in the art. But a problem associated with these drugs is that not all are once a day formulations and also if some are, they require an additional dose of a beta agonist to substantiate the combination.
Even from the patient compliance point of view, the treatment calls for the patient to comply with different dosage regimens, different frequencies of administration, etc. Also, since most of the medications are in the form of aerosols, the patient is required to carry several formulations and dispensers.
Thus there remains a need to formulate and also offer to the patient a combination that needs to be taken once a day and where the patient does not have to take another dose of beta- agonist or any other to substantiate the combination dose. - Object of the Invention:
It is an object of the present invention is to provide combinations of inhalable medicaments for administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
It is another object of the present invention to provide combinations of inhalation medicaments for administration once daily.
It is yet another object of the present invention to provide a method of formulating such novel combinations.
Summary:
According to a first aspect of the present invention there is provided a pharmaceutical combination comprising at least two active substances for once daily administration by inhalation route.
According to another aspect of the present invention there is provided a method of manufacturing said pharmaceutical combination comprising at least two active substances for once daily administration by inhalation route.
According to still another aspect of the present invention there is provided a pharmaceutical combination comprising at least two active substances for once daily administration by inhalation route administration in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
Description:
As discussed above, there is a long felt want in the art for an effective once daily formulation. The present invention provides novel combinations comprising two or more actives for administration once daily. The actives may be selected from various classes consisting of bronchodilators and corticosteroids and mixtures thereof. The bronchodilators may be either beta-agonists or anticholinergics or both.
The present inventors have surprisingly found that a combination of two or more bronchodilators and / or combination of two or more bronchodilators in combination with . corticosteroids shows a synergistic effect by relaxing both the central and peripheral air pathways improving the airflow obstruction, prolonged bronchodilation and provides rapid onset of action with reduced exacerbations.
Pharmaceutically active agents useful in the present invention include one or more of drugs selected from various classes consisting of bronchodilators and corticosteroids and mixtures thereof. The bronchodilators may be beta-agonists and/or anticholinergics. The terms "beta- agonist agent" or "beta-agonist" or "anticholinergic agent" or "corticosteroids" are used in broad sense to include not only the beta-agonist or anticholinergic agent per se but also their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, etc.
The beta-agonists may be selected from formoterol, AR-formoterol, fenoterol, carmoterol, indacaterol and the like. Formoterol may be present in an amount ranging from about 4.5- 96 meg, AR-formoterol may be present in an amount ranging from 1.25-96 meg, carmoterol may be present in an amount ranging from 0.5-16 meg, and indacaterol may be present in an amount ranging from 25-800 meg.
The anticholinergic may be aclidinium, ipratropium, tiotropium, oxitropium and the like. Tiotropium may be present in an amount ranging from 4.5 - 160 meg. Aclidinium may be present in an amount ranging from 50 - 900 meg.
The corticosteroid may be budesonide, ciclesonide, mometasone, beclomethasone and the like. Ciclesonide may be present in an amount ranging from 40-2880 meg and mometasone present in an amount ranging from 25-2000 meg. In one preferred embodiment of the present invention, the beta agonist is carmoterol, the corticosteroid is ciclesonide and the anticholinergic is tiotropium. In another preferred embodiment of the present invention, the beta agonist is carmoterol and the corticosteroid is ciclesonide. In yet another preferred embodiment of the present invention, the anticholinergic is tiotropium and the beta agonist is carmoterol. In yet another preferred embodiment of the present invention, the anticholinergic is aclidinium and the beta agonist is formoterol and/or AR-formoterol.
The formulations of the present invention are suitable for use in metered dose inhalers (MDI) (or aerosols). MDIs are compact drug delivery systems that use a liquefied propellant to atomize a precisely metered volume of a pharmaceutical formulation into particles, which are small enough to penetrate deep into the patient's lungs. MDIs allow for targeted delivery of drug to the desired site of the therapeutic effect - the lung.
The pharmaceutical combination may further be combined with one or more pharmaceutically acceptable excipients in order to provide a suitable formulation. The combination may, for example, be formulated as a propellant free inhalation solution for nebulization, as an aerosol composition (with propellant), or as dry powder composition for inhalation.
In case of dry powder inhalation formulations, the drugs may be used alone or optionally together with a finely divided pharmaceutically acceptable carrier, which is preferably present and may be chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides; and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol.
Preferably, the pharmaceutically acceptable carrier in the dry powder inhalation formulation is lactose. The carrier is preferably present in an amount not less that 75% by weight of the formulation. The dry powder may be provided in capsules of gelatin or HPMC or in blisters or alternatively, the dry powder may be contained as a reservoir either in a single dose or multi- dose dry powder inhalation device. The particle size of the active ingredient and that of the carrier where present in dry powder compositions, can be reduced to the desired level by conventional methods, for example by grinding in an air-jet mill, ball mill or vibrator mill, microprecipitation, spray-drying, lyophilization or recrystallization from supercritical media.
According to a preferred embodiment, the above dry powder composition may be manufactured by any convenient means wherein the process comprises of two or more drugs being mixed optionally with a pharmaceutically acceptable carrier and providing the ingredients in a suitable dry powder inhaler.
In case of inhalation solutions or nebulizing solutions, the drugs may be combined with suitable excipients such as wetting agents, tonicity adjusting agents, pH regulators, buffering agents and chelating agents, in a suitable vehicle. The wetting agents may be selected from the group consisting of sodiumdioctylsulfosuccinate; polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 65, polysorbate 85; sorbitan fatty acid esters such as Span 20, Span 40, Span 60 Span 80, Span 120; sodium lauryl sulfate; polyethoxylated castor oil; polyethoxylated hydrogenated castor oil and the like. The preferred wetting agent is one or more polysorbates, either alone or in combination with another wetting agent. The amount of wetting agent (especially when it includes a polysorbate) is in a range of 0.001 to 0.1% w/v of the composition.
The tonicity-adjusting agent, which may be used in the present invention, may include one or more of sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof. The preferred tonicity adjusting agent is sodium chloride.
The pH regulator may be selected from pharmacologically acceptable inorganic acids or organic acids, such as sodium hydroxide, sodium carbonate, sodium bicarbonate, magnesium carbonates, aluminium hydroxide, aluminum carbonate, aluminium bicarbonate, calcium carbonate and calcium hydroxide, calcium bicarbonate and the like. The preferred inorganic acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid and the like. The preferred organic acids are selected from the group consisting of ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid. The most preferred inorganic acids are hydrochloric acid & sulphuric acid, while, for the organic acids, ascorbic acid, citric acid and fumaric acid are the most preferred.
The pH regulators may be selected from pharmacologically acceptable inorganic bases or organic bases. The preferred inorganic bases are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide. The preferred organic bases are selected from the group consisting of methyl amine, ethyleneimine, hydroquinone, ethylamine, dimethylamine, ethanolamine, butylamine, diethylamine. The most preferred base is sodium hydroxide.
Preferably a nasal inhalation formulation as provided by the present invention has a pH in the range of 3.0 to 7.0.
In a preferred embodiment, suitable chelating or complexing agents are used in the inhalation solutions, and may be molecules which are capable of entering into complex bonds.
Preferable those compounds should have the effect of complexing cations most preferably metal cations. The formulations according to the invention preferably contain EDTA or one of the known salts thereof, e.g. sodium EDTA or disodium EDTA dihydrate, as complexing agent. The preferred agent is ethylenediaminetetraacetic acid (EDTA) or a salt thereof, such as the disodium salt.
In a preferred embodiment, suitable buffering agents that may be used in the inhalation solutions include citric acid and sodium or potassium citrates; or phosphates like trisodium phosphate, disodium or trisodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, tripotassium hydrogen phosphate and the like.
Suitable liquid vehicles for use in the compositions of the invention (particularly inhalation solutions or suspensions) include polar solvents, such as compounds that contain hydroxyl groups or other polar groups. Such solvents may include water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
Suitable polar solvents also include protic solvents, such as water, one or more aqueous saline solutions with one or more pharmaceutically acceptable salt(s), one or more alcohols, one or more glycols or a mixture thereof. For a saline solution as the solvent or as a component thereof, particularly suitable salts are those which display no or only negligible pharmacological activity after administration.
An anti-microbial preservative agent may be added for multi-dose packages. Suitable preservatives will be apparent to the skilled person, particularly benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate, sorbic acid or sorbates such as potassium sorbates in the concentration known from the prior art. The most preferred preservative is benzalkonium chloride.
According to a preferred embodiment, the above inhalation or nebulizer composition may be manufactured by any convenient means wherein the process comprises dissolving two or more drugs and optionally chelating agents, tonicity adjusting agents and any other suitable ingredient in a vehicle and adjusting the pH using a suitable pH adjusting agent. Further, finally, providing the said composition in a suitable dispensing container (such as a nebulizer) for inhalation.
According to another preferred embodiment, the above composition can be manufactured by convenient means wherein the process comprises sterilization of the active/s by known processes such as dry heat sterilization, moist heat sterilization, gamma radiation. The sterilized active/s is/are placed in a container and sterile bulk of other pharmaceutically acceptable ingredients comprising one or more of wetting agents, tonicity adjusting agents, pH regulators, chelating agents, buffering agents are transferred aseptically in the container with the API. The mixture may then be subjected to mixing either by sonication or magnetic stirring or by other means known in the art and finally, adding the above solution to the remaining bulk. In case of formulations which are in the form of pressurized aerosols using MDIs, the formulations may comprise one or more of cosolvents, antioxidants, surfactants, bulking agents and lubricants, in addition to the actives and propellant.
In one embodiment of the present invention the actives may be combined with one or more propellants.
The present invention includes at least one propellant such as propellant 11 (dichlorodifluoromethane), propellant 12 (monofluorotrichloromethane), Propellant 114, 1,1,1 ,2-tetrafiuoroethane, 1 , 1 , 1 ,2,3 ,3 ,3 -heptafluoroethane
hi one embodiment of the present invention the actives may be combined with either propellant 11 or propellant 114 or a combination thereof of and propellant 12 with surface- active agents known in the art.
The surfactants may be selected from the vast class known in the art like oils such as corn oil, olive oil, cottonseed oil and sunflower seed oil, mineral oils like liquid paraffin, oleic acid and also phospholipids such as lecithin, or sorbitan fatty acid esters like sorbitan trioleate or Tween 20, Tween 60, Tween 80, PEG - 25 Glyceryl trioleate, PVP, citric acid, PFDA (per fluoro-n-decanoic acid) The use of surfactants leads to comparatively good suspension quality. One of the preferred surfactants is lecithin. The surfactant can be used in a concentration of 0.001-100%. Preferably in a range of 1% - 50%. More preferably in a concentration of 5% - 30%. These concentrations are based on the weight of the active material(s).
In another embodiment of the present invention the actives and the surfactant can be micro- milled with propellant, preferably propellant 11 or propellant 114 or a combination thereof, to form a slurry and then the slurry can be filled in canisters. The actives can be micro-milled separately or together with the propellant. Micro-milling can be done to improve the suspension quality which inurn results in a better FPD.
There is also provided by the present invention a method for the manufacture of CFC aerosol which process comprises: (a) optionally micro- milling the drugs and surfactant with a propellant, preferably either propellant 11 or propellant 114 or a combination thereof; (b) filling the slurry in the canisters; (c) crimping with a suitable valve; and (d) charging with a propellant, preferably propellant 12, through the valve.
In yet another embodiment of the present invention the aerosol composition may comprise actives and either 1,1,1,2-tetrafluoroethane (HFA134a) or 1,1,1,2,3,3,3-heptafluoroethane (HFA227) or a combination thereof.
Another embodiment of the present invention may comprise actives, propellant and a cosolvent. In such a case the cosolvent has a greater polarity than the propellant. Typically the cosolvent is present in a proportion of 0.2 to 20% by weight of the total formulation. The cosolvent used may be selected from the group consisting of glycols, particularly propylene glycol, polyethylene glycol and glycerol or ethanol and mixtures thereof. Typically the cosolvent is ethanol.
The present invention also provides a method for the manufacture of the above composition which method comprises (a) Addition of the active ingredients to the canister, (b) Addition of the cosolvent optionally to (a) and sonication of the same, (c) Crimping the canister with the metered valve (d) charging the canister with the propellant.
In yet another embodiment the present invention may comprise the actives, propellant, surface-active agent and cosolvent.
The surface-active agent stabilizes the formulation and helps in the lubrication of a valve system in the inhaler. Some of the most commonly used surface active agents are those known in the art and can be selected from among various polysorbates such as Polysorbate 20, Polysorbate 40, Polysorbate 80; Acetylated monoglycerides like Myvacet 9-45 and Myvacet 9-08; isopropylmyristate, oleic acid, Polyoxyethylene ethers, ethyloleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oils, polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, polyethoxylated sorbitan fatty acid esters (for example polyethoxylated sorbitan trioleate), sorbimacrogol oleate, synthetic amphotensides (tritons), ethylene oxide ethers of octylphenolformaldehyde condensation products, phosphatides such as lecithin, polyethoxylated fats, polyethoxylated oleotriglycerides and polyethoxylated fatty alcohols.
The surface-active agents are preferably used in a concentration of 0.02 - 10% by weight of the active ingredients.
The present invention also provides a method for the manufacture of the above composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the cosolvent and the surfactant solution to (a) and sonication of the same; (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
Another embodiment of the present invention comprises the actives along with bulking agent and propellant.
The bulking agent acts as a carrier for the drug to reach the lungs. The bulking agent may be present in a concentration of 10-500% by weight of the active. More preferably in a range of 10-300% by weight of the active. The bulking agent may be selected from the class of saccharides, including monosaccharides, disaccharides, polysaccharides; and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol. The preferred bulking agent is lactose.
The present invention also provides a method for the manufacture of the above aerosol composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the bulking agent to (a); (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
Yet another embodiment of the present invention comprises the actives along with surfactant and propellant.
The surfactant may be selected from the class of salts of stearic acids or esters such, as ascorbyl palmitate, isopropyl myristate and tocopherol esters. The surfactant is preferably the magnesium salt of stearic acid or isopropyl myristate. Most preferably the surfactant is magnesium stearate. The surfactant is preferably used in a concentration of 0.01% to 10% by weight of the active.
The present invention also provides a method for the manufacture of the above aerosol composition which method comprises: (a) addition of the active ingredients to the canister; (b) addition of the surfactant to (a); (c) crimping the canister with a metered valve; and (d) charging the canister with the propellant.
In yet another embodiment one or more actives can be spray-coated or spray-dried or co- precipitated. The spray coating, spray drying or co-precipitation may be done by mixing the active in a solution of surface active agents in a suitable non-polar solvent and further removing the solvent.
In a further aspect of the present invention there is provided a method for the treatment in a mammal, such as a human, of chronic obstructive pulmonary disease, which method comprises administration of a therapeutically effective amount ranging from a pharmaceutical composition according to the present invention.
The MDI formulations may be in plain aluminium cans or SS (stainless steel) cans. Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the cans and valves, of the
MDI. This can lead to the patient getting significantly less than the prescribed amount of the active agent upon each activation of the MDI. Coating the inner surface of the container with a suitable polymer can reduce this adhesion problem. Suitable coatings include fluorocarbon copolymers such as FEP-PES (fluorinated ethylene propylene and polyethersulphone) and PFA-PES (perfluoroalkoxyalkane and polyethersulphone), epoxy and ethylene.
Alternatively, the inner surfaces of the cans may be anodized.
The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by the preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered to be falling within the scope of the invention.
Example 1
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with a propellant, which is preferably HFA P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000014_0001
Example 2
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with lactose and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000014_0002
Figure imgf000015_0001
Example 3
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide (spray coated with PVP), with lactose and a propellant, which is preferably HFA P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000015_0002
Example 4
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with PEG 100 and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000015_0003
Example 5 An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, oleic acid, and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000016_0001
Example 6
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000016_0002
Example 7
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, sorbitan trioleate, citric acid and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000017_0001
Example 8
An aerosol formulation was prepared using formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin, hydrochloric acid, and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000017_0002
Example 9
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with a propellant, which is preferably HFA P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000018_0001
Example 10
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with lactose and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000018_0002
Example 11
An aerosol foπnulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide spray coated with PVP, with lactose and a propellant, which is preferably HFA P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000018_0003
Figure imgf000019_0001
Example 12
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with PEG 100 and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000019_0002
Example 13
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, oleic acid and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000019_0003
Example 14
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000020_0001
Example 15
An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, sorbitan trioleate, citric acid and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000020_0002
Example 16 An aerosol formulation was prepared using AR-formoterol and aclidinium or a salt thereof, preferably aclidinium bromide, with absolute alcohol, lecithin, hydrochloric acid and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000021_0001
Example 17
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12. The amounts of the materials is preferably as shown in the table:
Figure imgf000021_0002
Example 18 An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with lecithin and a propellant, which is preferably Propellant 1 1 and Propellant 114 in combination with Propellant 12. The amounts of the materials is preferably as shown in the table:
Figure imgf000022_0001
Example 19
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with oleic acid and a propellant, which is preferably Propellant 11 and Propellant 12. The amounts of the materials is preferably as shown in the table:
Figure imgf000022_0002
Example 20
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with sorbitan trioleate and a propellant, which is preferably Propellant 11 and Propellant 12. The amounts of the materials is preferably as shown in the table:
Figure imgf000023_0001
Example 21
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with oleic acid and a propellant, which is preferably Propellant 11 and Propellant 114 in combination with Propellant 12 . The amounts of the materials is preferably as shown in the table:
Figure imgf000023_0002
Example 22
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with sorbitan trioleate and a propellant, which is preferably Propellant 11 and Propellant 114 in combination with Propellant 12. The amounts of the materials is preferably as shown in the table:
Figure imgf000024_0001
Example 23
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000024_0002
Example 24
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000024_0003
Figure imgf000025_0001
Example 25
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with ethanol and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000025_0002
Example 26
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with ethanol and a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000025_0003
Example 27
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with oleic acid, ethanol and a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000026_0001
Example 28
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with oleic acid, ethanol and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000026_0002
Example 29 An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with lactose and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000027_0001
Example 30
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with lactose and a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000027_0002
Example 31
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with magnesium stearate and a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000028_0001
Example 32
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, carmoterol, or a salt thereof, and ciclesonide, with magnesium stearate and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000028_0002
Example 33
An aerosol formulation was prepared using carmoterol, or a salt thereof, and ciclesonide, with isopropyl myristate and a propellant, which is preferably Propellant P227. The amounts of the materials is preferably as shown in the table:
Figure imgf000028_0003
Figure imgf000029_0001
Example 34
An aerosol formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate and carmoterol, or a salt thereof, with isopropyl myristate and a propellant, which is preferably HFA 134a. The amounts of the materials is preferably as shown in the table:
Figure imgf000029_0002
According to the following examples 35 to 39, the present invention may be manufactured by convenient means wherein the process comprises of one or more drugs being mixed optionally with a pharmaceutically acceptable carrier and providing the ingredients in a suitable dry powder inhaler ready for inhalation..
Example 35
An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with lactose. The amount of the materials is preferably as shown in the table:
Figure imgf000029_0003
Example 36
An dry powder formulation was prepared using carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide and lactose. The amount of the materials is preferably as shown in the table:
Figure imgf000030_0001
Example 37
An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide and lactose. The amount of the materials is preferably as shown in the table:
Figure imgf000030_0002
Example 38 An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and formoterol, or a salt thereof, preferably formoterol fuinarate dehydrate in combination with budesonide and lactose. The amount of the materials is preferably as shown in the table:
Figure imgf000031_0001
Example 39
An dry powder formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and formoterol, or a salt thereof, preferably formoterol fumarate dehydrate in combination with budesonide and lactose. The amount of the materials is preferably as shown in the table:
Figure imgf000031_0002
According to the following examples 40 to 42, the present invention may be carried out by a process comprising placing a sterile active(s) in a suitable container, then, aseptically adding the sterile bulk of other ingredients to the container having the active(s) and mixing the above solution by sonication or magnetic stirring and finally adding the above mixture to the remaining bulk. Example 40
An inhalation solution formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide, Tween 20, sodium chloride and water. The amount of the materials is preferably as shown in the table:
Figure imgf000032_0001
Example 41
An inhalation solution formulation was prepared using carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with ciclesonide, Tween 20, sodium chloride and water. The amount of the materials is preferably as shown in the table:
Figure imgf000032_0002
Example 42
An inhalation solution formulation was prepared using tiotropium or a salt thereof, preferably tiotropium bromide monohydrate, and carmoterol, or a salt thereof, preferably carmoterol hydrochloride in combination with sodium chloride and water. The amount of the materials is preferably as shown in the table:
Figure imgf000033_0001
Example 43
An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12. The amount of the materials is preferably as shown in the table:
Figure imgf000033_0002
Example 44 An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and ciclesonide, in combination with lecithin and a propellant, which is preferably Propellant 1 1 and Propellant 12. The amount of the materials is preferably as shown in the table:
Figure imgf000034_0001
Example 45
An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with a propellant, which is preferably HFAl 34a. The amount of the materials is preferably as shown in the table:
Figure imgf000034_0002
Example 46 An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and budesonide, in combination with lactose and a propellant, which is preferably HFA 227. The amount of the materials is preferably as shown in the table:
Figure imgf000035_0001
Example 47
10 An aerosol formulation was prepared using tiotropium or a salt thereof, formoterol, and ciclesonide, in combination with a propellant, which is preferably HFA 134a. The amount of the materials is preferably as shown in the table:
Figure imgf000035_0002
15
Example 48
An aerosol formulation was prepared using carmeterol, or a salt thereof, ciclesonide, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 20 12. The amount of the materials is preferably as shown in the table:
Figure imgf000036_0001
Example 49
An aerosol formulation was prepared using ciclesonide and formoterol, in combination with lecithin and a propellant, which is preferably Propellant 11 and Propellant 12. The amount of the materials is preferably as shown in the table:
Figure imgf000036_0002
Example 50
An aerosol formulation was prepared using carmoterol or a salt thereof and ciclesonide, in combination with a propellant, which is preferably HFA 134a. The amount of the materials is preferably as shown in the table:
Figure imgf000036_0003
Example 51
An aerosol formulation was prepared using formoterol and ciclesonide, in combination with a propellant, which is preferably HFA 134a. The amount of the materials is preferably as shown in the table:
Figure imgf000037_0001
Example 52
An aerosol formulation was prepared using formoterol and ciclesonide, in combination with ethanol, lecithin and a propellant, which is preferably HFA 227. The amount of the materials is preferably as shown in the table:
Figure imgf000037_0002
It is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having" and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. It must be noted that, as used in this specification, the singular forms "a," "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a propellant" includes a single propellant as well as two or more different propellants; reference to a "cosolvent" refers to a single cosolvent or to combinations of two or more cosolvents and the like.
It will be appreciated that the invention described above may be modified within the scope of the claims.

Claims

CLAIMS:
1. A pharmaceutical combination comprising (a) a combination of two or more bronchodilators for simultaneous or sequential administration; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid for simultaneous or sequential administration.
2. A pharmaceutical combination according to claim 1, comprising a combination of at least two bronchodilators in combination with at least one corticosteroid.
3. A pharmaceutical combination according to claim 1 or 2, wherein (a) the combination comprises bronchodilators selected from anticholinergic agents or beta adrenergic agonists or a combination thereof or (b) the combination comprises at least one bronchodilator in combination with atleast one corticosteroid.
4. A combination according to claim 1 or 2 or 3, which is for once daily administration.
5. A combination according to claim 1, 2, 3 or 4 wherein at least one of the bronchodilators is a beta-agonist.
6. A combination according to claim 5, wherein the or each beta- agonist is selected from formoterol, AR-formoterol, fenoterol, carmoterol and indacaterol, or a pharmaceutically acceptable salt or ester thereof.
7. A combination according to claim 5 or 6, wherein the beta-agonist is formoterol, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from about 4.5- 96 meg.
8. A combination according to claim 5 or 6 or 7, wherein the beta-agonist is AR- formoterol, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 1.25-96 meg
9. A combination according to claim 5, 6, 7 or 8 wherein the beta-agonist is carmoterol, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 0.5- 16 meg.
5 10. A combination according to claim 5, 6, 7, 8 or 9 wherein the beta-agonist is indacaterol, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 25-800 meg.
1 1. A combination according to any one of the preceding claims, wherein at least one of 10 the bronchodilators is an anticholinergic agent.
12. A combination according to claim 11, wherein the anticholinergic agent is selected from aclidinium, ipratropium, tiotropium and oxitropium, or a pharmaceutically acceptable salt or ester thereof.
15
13. A combination according to claim 11 or 12, wherein the anticholinergic agent is tiotropium, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 4.5 - 160 meg.
20 14. A combination according to claim 11, 12 or 13, wherein the anticholinergic agent is aclidinium, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 50 - 900 meg.
15. A combination according to any one of the preceding claims, wherein the 25 corticosteroid is selected from budesonide, ciclesonide, mometasone and beclomethasone, or a pharmaceutically acceptable salt or ester thereof.
16. A combination according to any preceding claim, wherein the corticosteroid is ciclesonide, or a pharmaceutically acceptable salt or ester thereof, present in an amount
30 ranging from 40-2880 meg
17. A combination according to any preceding claim, wherein the corticosteroid is mometasone, or a pharmaceutically acceptable salt or ester thereof, present in an amount ranging from 25-2000 meg.
5 18. A combination according to any preceding claim, wherein the bronchodilators are carmoterol and tiotropium and the corticosteroid is ciclesonide, or a pharmaceutically acceptable salt or ester thereof.
19. A combination according to any one of claims 1 to 14, wherein the bronchodilators 10 are tiotropium and carmoterol, or a pharmaceutically acceptable salt or ester thereof.
20. A combination according to any one of claims 1 to 17, wherein the bronchodilator is carmoterol and the corticosteroid is ciclesonide, or a pharmaceutically acceptable salt or ester thereof.
15
21. A combination according to any one of claims 1 to 14, wherein the bronchodilators are aclidinium and formoterol and/or AR-formoterol, or a pharmaceutically acceptable salt or ester thereof,.
20 22. A combination composition according to any preceding claims wherein all the active materials and any excipients are formulated in a single pharmaceutical composition.
23. A combination composition according to any preceding claim, formulated as an aerosol.
25
24. A combination composition according to any one of claims 1 to 22, formulated for use in a metered dose inhaler.
25. A combination composition according to claim 23 or 24, further comprising a 30 propellant.
26. A combination composition according to claim 23, 24 or 25, further comprising at least one excipient selected from a cosolvent, an antioxidant, a surfactant, a bulking agent and a lubricant.
5 27. A combination composition according to any one of claims 1 to 22, formulated for use as a dry powder inhalation formulation.
28. A combination composition. according to claim 27, further comprising at least one finely divided pharmaceutically acceptable carrier suitable for use in dry powder inhalation
10 formulations.
29. A combination composition according to claim 28, wherein said carrier includes a saccharide and/or a sugar alcohol.
15 30. A combination composition according to claim 28 or 29, wherein said carrier includes lactose, present in an amount comprising at least 75 wt% of the combination.
31. A combination composition according to any one of claims 1 to 22, formulated for use as an inhalation solution.
20
32. A combination composition according to any one of claims 1 to 22 formulated for use as a nebulizing solution.
33. A combination composition according to claim 32, further comprising at least one
25 excipient selected from a wetting agent, a tonicity adjusting agent, a pH regulator, a buffering agent and a chelating agent, provided in a pharmaceutically acceptable vehicle.
34. A combination according to any preceding claim for use in therapy.
30 35. A combination according to any preceding claim for use in the prevention or treatment of respiratory, inflammatory or obstructive airway disease.
36. A method of treating or preventing respiratory, inflammatory or obstructive airway disease comprising administering an effective amount of a pharmaceutical combination according to any one of claims 1 to 33 to a patient in need thereof.
37. A metered dose inhaler comprising a container, a pharmaceutical combination according to claim 23, 24, 25 or 26 disposed within the container, and a valve for metering a dose of the pharmaceutical combination from the container.
38. A metered dose inhaler according to claim 37, wherein the container is aluminium or stainless steel.
39. A metered dose inhaler according to claim 37 or 38, wherein an inner wall of the container is coated with a polymer capable of reducing adhesion of the pharmaceutical combination to said inner wall.
40. A metered dose inhaler according to claim 39, wherein the polymer coating is a fluorocarbon copolymer, an epoxy polymer and or an ethylene polymer or copolymer.
41. A metered dose inhaler according to claim 40, wherein the fluorocarbon polymer is a polymer of fluorinated ethylene propylene and polyethersulphone; or perfluoroalkoxyalkane and polyethersulphone.
42. A metered dose inhaler according to any one of claims 37 to 41 , wherein the inner surface of the container is anodized.
PCT/GB2008/000578 2007-02-19 2008-02-19 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid WO2008102128A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP08709463A EP2124915A2 (en) 2007-02-19 2008-02-19 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
CA002677573A CA2677573A1 (en) 2007-02-19 2008-02-19 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
MX2009008794A MX2009008794A (en) 2007-02-19 2008-02-19 Pharmaceutical combinations.
US12/527,096 US20100063016A1 (en) 2007-02-19 2008-02-19 Pharmaceutical Combinations
JP2009549477A JP2010519195A (en) 2007-02-19 2008-02-19 Pharmaceutical composition
AU2008217586A AU2008217586A1 (en) 2007-02-19 2008-02-19 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
US13/683,162 US20130074834A1 (en) 2007-02-19 2012-11-21 Pharmaceutical Combinations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN314MU2007 2007-02-19
IN314/MUM/2007 2007-02-19
IN1642/MUM/2007 2007-08-27
IN1642MU2007 2007-08-27
IN2179MU2007 2007-11-01
IN2179/MUM/2007 2007-11-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/683,162 Continuation US20130074834A1 (en) 2007-02-19 2012-11-21 Pharmaceutical Combinations

Publications (2)

Publication Number Publication Date
WO2008102128A2 true WO2008102128A2 (en) 2008-08-28
WO2008102128A3 WO2008102128A3 (en) 2009-01-08

Family

ID=39523694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000578 WO2008102128A2 (en) 2007-02-19 2008-02-19 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid

Country Status (11)

Country Link
US (2) US20100063016A1 (en)
EP (2) EP2124915A2 (en)
JP (1) JP2010519195A (en)
KR (1) KR20090121338A (en)
AU (1) AU2008217586A1 (en)
CA (1) CA2677573A1 (en)
CL (1) CL2008000500A1 (en)
MX (1) MX2009008794A (en)
PE (1) PE20081788A1 (en)
WO (1) WO2008102128A2 (en)
ZA (1) ZA200905615B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048384A3 (en) * 2008-10-23 2010-09-02 Sepracor Inc. Arformoterol and tiotropium compositions and methods for use
WO2011037549A3 (en) * 2009-09-23 2011-06-09 Bilgic Mahmut Dry powder formulation of tiotropium carried in blister strip
WO2011037551A3 (en) * 2009-09-23 2011-06-09 Mahmut Bilgic Carrying of a combination containing tiotropium in a blister strip
WO2011078818A1 (en) * 2009-12-25 2011-06-30 Bilgic Mahmut Dry powder combination of tiotropium, a corticosteroid and a cromoglicic acid derivative
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011049540A3 (en) * 2009-10-20 2011-11-03 Mahmut Bilgic The pharmaceutical composition in dry powder form for inhalation
CN102247380A (en) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 Compound preparation with budesonide and indacaterol as the active components
WO2012010854A1 (en) * 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
WO2011093812A3 (en) * 2010-01-28 2012-02-02 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093809A3 (en) * 2010-01-28 2012-02-23 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and ciclesonide
WO2011093819A3 (en) * 2010-01-28 2012-02-23 Mahmut Bilgic New pharmaceutical combination comprising tiotropium
JP2012507574A (en) * 2008-11-04 2012-03-29 シプラ・リミテッド Pharmaceutical aerosol composition
WO2012007729A3 (en) * 2010-07-16 2012-05-31 Cipla Limited Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
JP2012528200A (en) * 2009-05-29 2012-11-12 パール セラピューティクス，インコーポレイテッド Compositions and related methods and systems for pulmonary delivery of long acting muscarinic antagonists and long acting Β2 adrenergic receptor agonists
US20130125884A1 (en) * 2008-03-13 2013-05-23 Almirall, S.A. Novel dosage and formulation
WO2013109218A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising carmoterol and ciclesonide
WO2013109220A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium, formoterol and budesonide
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
US20130189317A1 (en) * 2008-03-13 2013-07-25 Almirall, S.A. Novel dosage and formulation
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
CN104363895A (en) * 2012-06-14 2015-02-18 韩美药品株式会社 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
WO2016090260A1 (en) 2014-12-04 2016-06-09 Microdose Therapeutx, Inc. Inhalation monitoring system and method
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN106620976A (en) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 Fluticasone propionate aerosol realizing quantitative inhalation
CN106619658A (en) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 Medical aerosol preparation and quantitatively-inhaled aerosol
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10040765B2 (en) 2012-09-21 2018-08-07 Crystal Pharma S.A.U. Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
US10179139B2 (en) 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhalable medicament comprising glycopyrronium
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US11844793B2 (en) 2020-09-29 2023-12-19 Aerorx Therapeutics Llc Liquid formulations of indacaterol

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130028977A1 (en) * 2010-03-31 2013-01-31 Glenmark Pharmaceuticals Limited Pharmaceutical powder composition for inhalation
US20130104881A1 (en) * 2011-10-31 2013-05-02 Laboratorio Pablo Cassara S.R.L. Stabilized Metered Dose Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
CN112804991B (en) * 2019-06-27 2022-03-11 广州谷森制药有限公司 Inhalable solution formulations containing formoterol fumarate and aclidinium bromide

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227519B1 (en) 1991-12-18 2011-07-28 Astra Ab Synergic pharmaceutical composition containing combination of formoterol and budesonide
SE9603669D0 (en) 1996-10-08 1996-10-08 Astra Ab New combination
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
SE9900834D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AU2001247123A1 (en) 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
WO2002036106A2 (en) 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
NZ538493A (en) * 2002-08-29 2007-10-26 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP1635845A1 (en) * 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
CA2534132C (en) * 2003-07-29 2013-11-26 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
JP2007500676A (en) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhalable drugs including anticholinergics and beta receptor stimulants
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
SE0303571D0 (en) 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive drugs
JO3102B1 (en) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
RS50786B (en) * 2004-05-31 2010-08-31 Laboratorios Almirall S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
DE102004056578A1 (en) * 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhaled drugs containing a new anticholinergic, formoterol and a steroid
EP1848444B1 (en) * 2005-02-10 2016-11-09 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
MX2007012084A (en) * 2005-03-30 2007-11-21 Schering Corp Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist.
US20070098644A1 (en) 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2124915A2 *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US20130125884A1 (en) * 2008-03-13 2013-05-23 Almirall, S.A. Novel dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US9254262B2 (en) * 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
EP2265258B1 (en) 2008-03-13 2015-10-07 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma
EP2265257B1 (en) 2008-03-13 2015-08-12 Almirall, S.A. Inhalation composition containing aclidinium for treatment of chronic obstructive pulmonary disease
EP2265257B2 (en) † 2008-03-13 2023-10-25 Almirall, S.A. Inhalation composition containing aclidinium for treatment of chronic obstructive pulmonary disease
US20130189317A1 (en) * 2008-03-13 2013-07-25 Almirall, S.A. Novel dosage and formulation
AU2009308412B2 (en) * 2008-10-23 2015-11-26 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
JP2014237666A (en) * 2008-10-23 2014-12-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Arformoterol and tiotropium composition and method for use
WO2010048384A3 (en) * 2008-10-23 2010-09-02 Sepracor Inc. Arformoterol and tiotropium compositions and methods for use
JP2012507574A (en) * 2008-11-04 2012-03-29 シプラ・リミテッド Pharmaceutical aerosol composition
JP2012528792A (en) * 2009-05-29 2012-11-15 パール セラピューティクス，インコーポレイテッド Compositions, methods and systems for respiratory delivery of two or more active agents
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP2018048150A (en) * 2009-05-29 2018-03-29 パール セラピューティクス，インコーポレイテッド Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists, and associated methods and systems
JP2017222706A (en) * 2009-05-29 2017-12-21 パール セラピューティクス，インコーポレイテッド Compositions, methods and systems for respiratory delivery of two or more active agents
JP2012528200A (en) * 2009-05-29 2012-11-12 パール セラピューティクス，インコーポレイテッド Compositions and related methods and systems for pulmonary delivery of long acting muscarinic antagonists and long acting Β2 adrenergic receptor agonists
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
JP2015199735A (en) * 2009-05-29 2015-11-12 パール セラピューティクス，インコーポレイテッド Composition, method and system for delivering two or more activators to respiratory organ
WO2011037549A3 (en) * 2009-09-23 2011-06-09 Bilgic Mahmut Dry powder formulation of tiotropium carried in blister strip
WO2011037551A3 (en) * 2009-09-23 2011-06-09 Mahmut Bilgic Carrying of a combination containing tiotropium in a blister strip
WO2011049540A3 (en) * 2009-10-20 2011-11-03 Mahmut Bilgic The pharmaceutical composition in dry powder form for inhalation
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
WO2011078818A1 (en) * 2009-12-25 2011-06-30 Bilgic Mahmut Dry powder combination of tiotropium, a corticosteroid and a cromoglicic acid derivative
WO2011093809A3 (en) * 2010-01-28 2012-02-23 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and ciclesonide
WO2011093812A3 (en) * 2010-01-28 2012-02-02 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011093819A3 (en) * 2010-01-28 2012-02-23 Mahmut Bilgic New pharmaceutical combination comprising tiotropium
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2012007729A3 (en) * 2010-07-16 2012-05-31 Cipla Limited Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
EP3871676A1 (en) * 2010-07-16 2021-09-01 Cipla Limited Pharmaceutical compositions comprising r(+) budesonide and arformoterol
US11077124B2 (en) 2010-07-16 2021-08-03 Cipla Limited Pharmaceutical compositions
WO2012010854A1 (en) * 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
US10179139B2 (en) 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102247380A (en) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 Compound preparation with budesonide and indacaterol as the active components
WO2013109218A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising carmoterol and ciclesonide
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
WO2013109220A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium, formoterol and budesonide
CN104363895A (en) * 2012-06-14 2015-02-18 韩美药品株式会社 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US10040765B2 (en) 2012-09-21 2018-08-07 Crystal Pharma S.A.U. Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP3583899A1 (en) 2014-12-04 2019-12-25 Norton (Waterford) Limited Inhalation monitoring system and method
EP3838319A1 (en) 2014-12-04 2021-06-23 Norton (Waterford) Limited Inhalation monitoring system and method
WO2016090260A1 (en) 2014-12-04 2016-06-09 Microdose Therapeutx, Inc. Inhalation monitoring system and method
CN106620976B (en) * 2016-12-28 2020-01-07 四川普锐特医药科技有限责任公司 Fluticasone propionate quantitative inhalation aerosol
CN106620976A (en) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 Fluticasone propionate aerosol realizing quantitative inhalation
CN106619658A (en) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 Medical aerosol preparation and quantitatively-inhaled aerosol
CN106619658B (en) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 Medical aerosol preparation and quantitative inhalation aerosol
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhalable medicament comprising glycopyrronium
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
US11844793B2 (en) 2020-09-29 2023-12-19 Aerorx Therapeutics Llc Liquid formulations of indacaterol

Also Published As

Publication number Publication date
US20100063016A1 (en) 2010-03-11
US20130074834A1 (en) 2013-03-28
EP2327403A3 (en) 2011-08-31
EP2124915A2 (en) 2009-12-02
KR20090121338A (en) 2009-11-25
WO2008102128A3 (en) 2009-01-08
JP2010519195A (en) 2010-06-03
CL2008000500A1 (en) 2008-09-05
MX2009008794A (en) 2009-08-25
ZA200905615B (en) 2011-03-30
PE20081788A1 (en) 2008-12-18
AU2008217586A1 (en) 2008-08-28
EP2327403A2 (en) 2011-06-01
CA2677573A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
US20130074834A1 (en) Pharmaceutical Combinations
EP2201964B1 (en) Formoterol superfine formulation
EP2749283A2 (en) Combination of glycopyrronium and olodaterol
AU2011315315A1 (en) Pharmaceutical composition
WO2014016548A2 (en) Pharmaceutical composition
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
EP2515856B1 (en) Aerosol Formulation for COPD
TWI449523B (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
AU2010320728A1 (en) Inhalation solutions
WO2012010854A1 (en) Inhalation formulations comprising carmoterol in combination with a corticosteroid
WO2009090009A1 (en) Pharmaceutical formulation comprising an anticholinergic drug
US20110182830A1 (en) Inhalation drug products, systems and uses
EA039998B1 (en) METHOD FOR REDUCING THE FREQUENCY OF COBL EXAMINATIONS OF MODERATE/SEVERE COBL

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08709463

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008217586

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2677573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 578961

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008709463

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008794

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009549477

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1541/MUMNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008217586

Country of ref document: AU

Date of ref document: 20080219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097019295

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009135033

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12527096

Country of ref document: US